IV. 4 Recognising recurrence and what to do

The possibility of recurrence is no reason for fear, if you know what to watch for. In this chapter you will learn to recognise the early signs, to tell a passing upset from a genuine relapse, and you will know exactly what to do – from the diary to the doctor.

The early signs: when your diary speaks before your feeling does

Recurrence rarely bursts in from one day to the next – there is usually a quiet, few-day prelude that your diary often shows before you consciously feel it. The most telling early sign is the stool slipping back: the daily stool count begins to rise again, and the Bristol value^[G] creeps from the normal 3–4 band towards the looser, more watery 6–7. Bloating, cramping abdominal discomfort and a fall in appetite may join it – symptoms you already know from the earlier stage of the illness.

This is where it becomes invaluable that you have been keeping the diary for weeks: there is something to compare against. A lone worse day means nothing in itself – everyone has those. The real warning is when the numbers worsen consistently, over several days, stepping out of the stable band you grew used to during remission^[G]. It is this trend that is the signal, not the single fluctuation.

That is why it is worth not stopping the recording even during stabilisation, even when you feel well. The diary is most useful precisely when everything is fine: against the calm baseline you can judge whether a change is a genuine slipping-back, or just the natural fluctuation of everyday life.

Passing upset or genuine recurrence – and what to do

The most common question at this point: "is this a relapse now, or did I just get something wrong?" The difference lies largely in durability and in the accompanying symptoms. A fattier meal, a stressful day or an upset stomach can cause one or two looser stools that settle on their own within a day. A genuine recurrence is indicated when the symptoms persist or strengthen over several days – the stool count rises persistently, the Bristol value stays stubbornly in the 6–7 range, and the overall picture typical of the illness returns.

If you see this, what to do is simple and calm: do not start raising the dose or taking medication on your own, but get in touch with your treating physician, and take the most recent days of your diary with you. The logic of treating recurrence is familiar from before: your doctor typically responds by restoring the maximum dose and a repeat course, and if repeated relapse warrants it, switches to a different LOT, that is, a different batch of the product. These decisions always require medical judgement – your job is the early signal and accurate data.

And there is a boundary that must be highlighted separately: with certain symptoms you should not wait for the appointment with your treating physician, but seek help immediately. We have gathered these warning signs in the box at the end of the chapter – if you see any of them on yourself, it is a matter of urgent medical care, not of weighing it up at home.

🍽️ Eating during these days

The theme of these days is recognising recurrence in time – and eating works on the preventive side of this: the varied, fibre-rich plate keeps strong the diverse gut flora that makes it harder for the pathogen to gain a foothold again. The concrete eating task for the three days: keep up the familiar fluid replacement and the other built-in lifestyle steps even when you feel well, and every day work the day's plant into at least one meal. If you notice looser stool or bloating after any new source, mark that separately in the diary – this way you can tell a food's transient effect from a sign of genuine slipping-back.

For these days (70–72), the Plant Calendar (Appendix F) brings sourdough wholemeal bread (70), then two inulin^[G]-rich vegetables – Jerusalem artichoke (71) and globe artichoke (72). Inulin is a strongly fermentable prebiotic^[G] fibre: a favourite food of the beneficial gut bacteria, from which they make short-chain fatty acids^[G] – including butyrate^[G]; this supports the gut barrier (Koh 2016 [111]; Baxter 2019 [483]). In the second half of the programme (about days 61–90) the goal is precisely to maintain full diversity^[G] and inulin-rich, fermentable sources, because a diverse, stable flora is the foundation of resilience^[G] – this is what makes the gut more resistant to recurrence. Inulin sources, however, can be more gas-forming, so introduce them according to your tolerance, in small portions; if they cause bloating, pull back and come back to them later.

Why does this matter?

Recognising recurrence is not about fear, but about preparedness. If you know your own stable normal, your diary often signals before your feeling does – and so you can act calmly, according to a plan. The early signal and accurate data are your job; the treatment decision (maximum dose, repeat course, different LOT) is your doctor's. And with the warning signs there is no weighing up: see a doctor immediately.

References

[020] Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scandinavian Journal of Gastroenterology. 1997. Link

The original validation of the Bristol Stool Form Scale. Whole-gut transit time was measured with radio-opaque marker pellets in 66 volunteers, who kept a diary of stool form on a 7-point scale and of defecation frequency. Transit time correlated most closely with stool form (r = -0.54), more strongly than with stool frequency or stool output. When transit time was altered with senna and with loperamide, stool form tracked the change (r = -0.65). Conclusion: recording stool form is a simple and responsive way to monitor change in bowel function — which is why it is suitable for the patient's own diary.

[032] Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, Wilson LE, Holzbauer SM, Phipps EC, Dumyati GK, Beldavs ZG, Kainer MA, Karlsson M, Gerding DN, McDonald LC; Emerging Infections Program Clostridioides difficile Infection Working Group. Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. N Engl J Med. 2020. Link

Updated US epidemiological surveillance demonstrating that the burden of healthcare-associated CDI declined substantially between 2011 and 2017 – by 36 percent according to the adjusted estimate (95% CI 24 to 54), according to the authors primarily as a result of the decline of ribotype 027 and, alongside it, improved infection control – while community-associated CDI remained stable. The estimated burden of first recurrences and of in-hospital mortality, however, did not change meaningfully. The authors conclude that better identification of patients at high risk of recurrence is needed, together with further strengthening of infection control and antibiotic stewardship; the paper does not discuss microbiota-restorative therapy. The unchanged burden of recurrences is the clinical gap that compatibility-based MTT addresses.

[111] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016. Link

Mechanistic review of short-chain fatty acids (SCFAs), produced by bacterial fermentation of dietary fibre. Fermentable fibre is the primary energy source for the colonic microbiota; the main fermentation products are **acetate, propionate and butyrate**. **Butyrate is the principal energy substrate of colonocytes**; SCFAs also influence barrier integrity, immune function and, once in the circulation, host metabolism, partly via G-protein-coupled receptors (GPR41/43) and histone deacetylase inhibition. This entry is the source for the textbook-level claims of III.2 (S-0302-01, -02). Important: a **review**, not original experimental data.

[157] Sheitoyan-Pesant C, Abou Chakra CN, Pepin J, Marcil-Heguy A, Nault V, Valiquette L. Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection. Clin Infect Dis. 2016. Link

Retrospective cohort of adults diagnosed with CDI at a hospital in Sherbrooke, Canada (1998–2013), assessing the burden of multiple recurrences. 1527 patients. The **probability of a first recurrence was 25%** (354/1418), of a **second 38%** (128/334), a third 29% (35/121), and a fourth or more 27% (9/33); two or more recurrences occurred in 9% of patients. The severity and complication risk of recurrences decreased with successive episodes. This entry is the source for the IV.4 claim that CDI recurrence risk is significant and rises with each further recurrence. **LIMITATION:** a single-centre retrospective cohort; the per-episode conditional probabilities (25%, 38%) are lower than the commonly cited cumulative ">60%" guideline estimate — which is why the handbook uses the specific cohort figures.

[483] Baxter NT, Schmidt AW, Venkataraman A, Kim KS, Martens EC, Schloss PD. Dynamics of Human Gut Microbiota and Short-Chain Fatty Acids in Response to Dietary Interventions with Three Fermentable Fibers. mBio. 2019. Link

Two-week dietary intervention in 174 healthy young adults supplementing with resistant starch from potatoes (RPS), resistant starch from maize (RMS), inulin, or accessible corn-starch control. RPS produced the greatest increase in total SCFAs including butyrate. Most microbiomes responded to RPS with increased bifidobacteria, but responders with rising Ruminococcus bromii or Clostridium chartatabidum showed the highest butyrate concentrations. The study demonstrates substrate- and taxon-specific routes to butyrate enrichment, informing personalized prebiotic strategies.